Janux Therapeutics, Inc. · NASDAQ:JANX
Prosight Management, LP reported a 5.30% stake in Janux Therapeutics, Inc. (Schedule 13G)
Event Feb 3, 2026 · Filed Feb 6, 2026
Prosight Management, LP reported a 5.30% stake in Janux Therapeutics, Inc., 3,157,220 shares, as a passive investor on Feb 3, 2026. Filed Feb 6, 2026 (Schedule 13G).
- Stake
- 5.30%
- Shares
- 3,157,220
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Prosight Management, LP | 5.20% | 3,150,970 |
| Prosight Fund, LP | 0.20% | 148,416 |
| Prosight Plus Fund, LP | 1.10% | 685,220 |
| Prosight Partners, LLC | 5.20% | 3,150,970 |
| W. Lawrence Hawkins | 5.30% | 3,157,220 |
Source
Related
- Janux Therapeutics, Inc.
- Prosight Management, LP
- Janux Therapeutics, Inc. shareholders
- Schedule 13G/A · Point72 Asset Management, L.P. · Aug 14, 2026
- Schedule 13G/A · Janus Henderson Group PLC · Aug 13, 2026
- Form 4 · Campbell David Alan · Jul 31, 2026
- Schedule 13G/A · BlackRock, Inc. · Jul 28, 2026
- Form 4 · Campbell David Alan · Jul 10, 2026